600488 津药药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,572,215-9.36%3,782,8273,688,9303,748,6653,116,848
减:营业总成本2,279,962-12.10%3,590,1763,485,9793,566,7212,951,809
    其中:营业成本1,429,443-1.45%2,026,6431,878,6681,963,0271,682,910
               财务费用8,897-22.94%17,21129,24845,23544,358
               资产减值损失(56,624)32.15%(57,226)(123,935)(53,351)(45,103)
公允价值变动收益------------
投资收益(428)-40.60%(1,126)(22,437)4,985(1,221)
    其中:对联营企业和合营企业的投资收益(431)-517.94%(266)(1,952)1,615(1,221)
营业利润253,42819.53%169,40770,208145,834132,421
利润总额255,37920.93%168,24012,517149,067112,380
减:所得税费用16,510-4.06%5,567(5,920)40,40031,805
净利润238,86923.15%162,67318,437108,66880,575
减:非控股权益52,17423.58%45,621(16,969)60,00046,596
股东净利润186,69523.03%117,05335,40648,66833,979

市场价值指针
每股收益 (元) *0.17123.02%0.1070.0320.0450.031
每股派息 (元) *----0.0870.0100.0140.010
每股净资产 (元) *2.789-2.28%2.7002.7112.7212.718
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容